tiprankstipranks
Advertisement
Advertisement

Adma Biologics sees FY25 revenue $485M, consensus $486.79M

Sees FY25 net income expected to exceed $170M; FY25 adjusted EBITDA expected to exceed $220M,

Claim 55% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1